11.30

1.31% -0.15

After Hours: 11.25 -0.05 -0.44%

Oculis Holding Ag (OCS)

Overview News Price History Discussions Forecast

Oculis Holding Ag stock is traded at $11.30, with a volume of 578.92K. It is down -1.31% in the last 24 hours and down -62.69% over the past month. Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Previous Close:

$11.45

Open:

$11.38

24h Volume:

578.92K

Relative Volume:

0.95

Market Cap:

$682.39M

Revenue:

Net Income/Loss:

$-117.99M

P/E Ratio:

-5.2811

EPS:

-2.1397

Net Cash Flow:

$-79.92M

1W Performance:

+3.01%

1M Performance:

-62.69%

6M Performance:

-41.84%

1Y Performance:

-42.73%

1-Day Range:

$11.20

$11.67

1-Week Range:

$10.80

$11.67

52-Week Range:

$10.52

$34.48

Oculis Holding Ag Stock (OCS) Company Profile

Name

Oculis Holding Ag

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

OCS's Discussions on Twitter

Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCS Oculis Holding Ag	11.30	701.11M	0	-117.99M	-79.92M	-2.1397
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Initiated	JP Morgan	Overweight
Aug-27-25	Initiated	Needham	Buy
Dec-05-23	Initiated	Chardan Capital Markets	Buy
Oct-05-23	Initiated	Stifel	Buy
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

View All

Oculis Holding Ag Stock (OCS) Latest News

Jun 15, 2026

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com

Jun 15, 2026

Oculis executive Sylvia Cheung reports June 10 share purchase - Stock Titan

Jun 15, 2026

Jun 14, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jun 14, 2026

Jun 13, 2026

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports

Jun 13, 2026

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com

Jun 13, 2026

Jun 12, 2026

OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill

Jun 12, 2026

Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN

Jun 12, 2026

Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times

Jun 12, 2026

Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang

Jun 12, 2026

Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang

Jun 12, 2026

Jun 11, 2026